Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - solutie perfuzabila - 50 mg/ml

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

gm pharmaceuticals ltd. - ceftriaxonum - pulbere si solvent pentru solutie injectabila - 1 g

Unió Europea - romanès - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil clorhidrat de - neoplasme colorectale - agenți antineoplazici - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Unió Europea - romanès - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplasme colorectale - antineoplastic agents, protein kinase inhibitors - stivarga este indicat în monoterapie pentru tratamentul pacienților adulți cu:cancer colorectal metastatic (crc), care au fost tratați anterior cu, sau nu sunt considerați candidați pentru, disponibile terapii - acestea includ chimioterapie pe bază de fluoropirimidine, un anti-vegf terapie și un anti-egfr terapie;inoperabil sau metastatic tumori stromale gastro-intestinale (gist), care a progresat sau intoleranță la tratamentul anterior cu imatinib și sunitinib;carcinom hepatocelular (hcc), care au fost anterior tratați cu sorafenib.

Unió Europea - romanès - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrita, reumatoida - imunosupresoare - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant poate fi utilizat ca monoterapie sau în asociere cu metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unió Europea - romanès - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetul zaharat - medicamente utilizate în diabet - diabet zaharat în care este necesară tratamentul cu insulină. insuman rapid este de asemenea potrivit pentru tratamentul hyperglycaemic comă şi cetoacidoza, precum şi pentru realizarea pre-, intra - şi stabilizare postoperatorie la pacienţii cu diabet zaharat.

Unió Europea - romanès - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriazis - imunosupresoare - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.